Evaluation of Cardiac Function by Transthoracic Echocardiography in Subjects with ST-Segment Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention according to Valsartan Dose: The Valsartan One Center Trial

Sung-Sik KIM; Hui-Kyung JEON; Gyu-Min CHO; Jong-Hwan LEE; Soo-Jung KIM; Mi-Youn PARK; Seung-Jae LEE; Byung-Ju SHIM; Dong-Hyeon LEE; Woo-Seung SHIN; Jong-Min LEE; Ho-Joong YOUN.
Journal of Cardiovascular Ultrasound ; : 77-83, 2010.
Artículo en Inglés | WPRIM | ID: wpr-207091

Documentos relacionados

  1. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
  2. Protective effect of sacubitril/valsartan (Entresto) on kidney function and filtration barrier injury in a porcine model of partial nephrectomy.
  3. Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series.
  4. The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.
  5. [Choice of Angiotensin Receptor Blocker at Various Stages of the Cardiovascular Continuum].
  6. Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.
  7. Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study.
  8. Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696.
  9. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
  10. Design and development of ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar albino rats.